LEGN

Business Context and Reporting Period

Company: Legend Biotech Corporation
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three months ended March 31, 2025
Report Date: May 13, 2025
Business Overview: Legend Biotech is a global biopharmaceutical company focused on cell therapies for oncology. Its lead product, CARVYKTI (ciltacabtagene autoleucel), is approved for multiple myeloma and is co-developed with Janssen Biotech (Johnson & Johnson). The company operates in the United States, China, and Europe.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 107% to $195.1 million, driven primarily by a $107.1 million increase in collaboration revenue ($185.6 million vs. $78.5 million) due to higher CARVYKTI sales. License revenue decreased $2.8 million due to timing of clinical trial activities with Novartis.
• Net Loss Expansion: Net loss widened to $100.9 million from $59.8 million. This was significantly impacted by a $54.5 million net expense in "Other (expense)/income," primarily due to a $55.2 million unrealized foreign exchange loss (USD vs. EUR), compared to a $49.1 million gain in the prior year.
• Operating Expenses: Selling and distribution expenses rose 69% to $41.0 million due to sales force expansion. Cost of collaboration revenue increased 42% to $69.5 million reflecting higher sales volume and manufacturing capacity expansion. R&D expenses remained relatively flat at $101.9 million.
• Liquidity Position: While cash and cash equivalents increased by $155 million, total time deposits decreased by $272 million due to redemptions. Total liquidity remains robust at approximately $1.0 billion.

Guidance, Outlook, and Risks

• Financial Runway: Management states that current cash, cash equivalents, and time deposits of $1.0 billion provide a financial runway into the second quarter of 2026.
• Profitability Outlook: The company anticipates potentially achieving an operating profit (excluding unrealized foreign exchange gains/losses) in the second quarter of 2026.
• Business Highlights: CARVYKTI net trade sales were approximately $369 million; over 6,000 patients treated to date. Clinical production initiated at the Tech Lane facility. Received positive CHMP opinion for label expansion in Europe.
• Risks and Contingencies:
  • Foreign Exchange: Significant volatility in reported earnings due to unrealized FX losses on intercompany loans and cash balances (USD/EUR).
  • Tariffs: Potential future tariffs on pharmaceutical ingredients could impact costs, though current US supply is domestically produced.
  • Capital Needs: Continued reliance on additional financing if operating profit targets are not met or if development costs exceed expectations.
  • Debt Structure: $250 million in principal advances from Janssen accrue interest based on SOFR + 2.5% margin, repayable from future collaboration profits.

Investor Verification Checklist

• FX Impact: Verify the magnitude of unrealized foreign exchange losses ($55.2 million) and their impact on the reported net loss versus Adjusted Net Loss ($27.0 million).
• Liquidity Composition: Confirm the breakdown of the $1.0 billion liquidity between liquid cash ($441.7 million) and time deposits ($563.7 million) to assess immediate working capital availability.
• Debt Obligations: Review the terms of the $305.7 million collaboration interest-bearing advanced funding from Janssen, specifically the recoupment mechanism from future profits.
• Revenue Sustainability: Assess the sustainability of the 107% revenue growth driven by CARVYKTI collaboration revenue and the timing of license revenue recognition.
• Runway Validity: Evaluate the assumption that current cash reserves will sustain operations until Q2 2026 given the $103.8 million quarterly cash burn from operations.